News
Novartis snaps up PI3Kα breast cancer drug in $3bn deal
Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.
Sales & Marketing
Sponsored
Using AI-driven synthetic personas to take your insights fur...
As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
Market Access
12 questions with: Daniel Kohlstaedt
Daniel Kohlstaedt, managing director of PurpleLeaf Strategy, with more than 18 years of experience in pharma, talks about his journey through the industry.
Digital
Sponsored
Expert Directed Applied Intelligence: Redefining AI in Life ...
In a new white paper from Lumanity, explore why the most powerful AI will always be human-directed.
Oncology
Hernexeos and what’s next, with Vicky Brown
At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Digital
Sponsored
Data managers and CRAs warn of rising data quality risks due...
A new industry report uncovers the scope of a long-ignored problem in clinical trial operations.
R&D
Partner Content
Emerging Trends in Personalised Medicine at PHARMAP 2026
The Pharmaceutical Manufacturing & Packaging Congress is an exclusive annual event that fosters networking and knowledge-sharing among professionals
R&D
Partner Content
5th mRNA-Based Therapeutics Summit Europe
The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines
Category :
Views & Analysis
/